Healthcare / BiotechnologyHKSE
$0.40
+0.00 (+1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-23.2M · quality 22.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
40.0x
↑EV/EBITDA
25.0x
↑ROE
36.3%
↑Gross Margin
88.8%
↑Debt/Equity
2.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+126.1%
FCF CAGR
—
FCF margin
-3.6%
FCF / Net income
-0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $646.1M · net income $57.1M · FCF $-23.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $646.1M | $646.1M | $258.2M | $87.2M | $55.9M |
| Net Income | $57.1M | $57.1M | $-127.9M | $-209.4M | $-210.8M |
| EBITDA | $74.8M | $74.8M | $-56.1M | $-139.1M | $-152.1M |
| EPS | — | — | -0.03 | -0.05 | -0.05 |
| Gross Margin | 88.8% | 88.8% | 85.0% | 86.3% | 72.5% |
| Operating Margin | 2.0% | 2.0% | -42.7% | -227.5% | -356.3% |
| Net Margin | 8.8% | 8.8% | -49.5% | -240.2% | -377.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.08 | 2.08 | 3.50 | 1.27 | 0.32 |
| Current Ratio | 0.81 | 0.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.2M | $-23.2M | $-63.6M | $38.4M | $-182.0M |
| Returns | |||||
| ROE | 36.3% | 36.3% | -143.9% | -102.1% | -52.6% |
| Valuation | |||||
| P/E | 40.00 | 40.00 | — | — | — |
| EV/EBITDA | 24.98 | 24.98 | — | — | — |
| P/B | 10.49 | 10.49 | 12.75 | 9.05 | 4.47 |
| Growth & Yield | |||||
| Revenue Growth | 150.2% | 150.2% | 196.3% | 55.9% | — |
| EPS Growth | — | — | 40.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
-14.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.